BioCentury
ARTICLE | Clinical News

REGN follow-up Phase II data

September 11, 2001 7:00 AM UTC

Regeneron (REGN) reported 36-week follow-up data from a Phase II trial showing patients given Axokine second generation ciliary neurotrophic factor ( CNTF) at the optimal dose of 1 ug/kg maintained th...